Cell death programs—apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy-coupled death—shape development, homeostasis, and disease. We provide marker antibodies (Caspase, PARP, Bcl-2 family, RIPK–MLKL, GSDMD, GPX4, etc.) and chemical probes across apoptosis/necroptosis/ferroptosis/inflammasome axes for mechanistic and phenotypic studies.
Focus areas: mitochondrial apoptosis & MOMP, death-receptor signaling, necrosome & membrane rupture, inflammasome–GSDMD axis, lipid peroxidation & ferroptosis
Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.
| Compound | Targets / pathways | Experimental notes |
|---|---|---|
| Z-VAD-FMK | Caspases (broad) | Classic apoptosis blockade; mind off-target toxicity—pair vehicle controls and time courses. |
| Q-VD-OPh | Caspases (context-dependent preference) | Often better tolerated than Z-VAD in vitro; pair with cleaved PARP/caspase and membrane integrity. |
| Necrostatin-1 (Nec-1) | RIPK1 kinase activity | Common necroptosis tool; mind isoforms/off-targets—cross-validate with genetics. |
| Ferrostatin-1 (Fer-1) | Lipid peroxidation / ferroptosis (radical trapping; context-dependent) | Pair with GPX4/ACSL4/lipidomics; separate ferroptosis from other oxidative death phenotypes. |
| Liproxstatin-1 | Ferroptosis (potent lipophilic antioxidant; model-dependent) | Often paired with Erastin/RSL3 induction; mitochondria/autophagy can confound. |
| MCC950 | NLRP3 inflammasome | Upstream of pyroptosis; pair with GSDMD cleavage and IL-1β release readouts. |
| Erastin | System Xc⁻ / ferroptosis induction (tool use) | Induces ferroptosis models—not cytoprotective; pair with Fer-1/Liproxstatin rescue. |